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Abstract 
Anticoagulant resistance was first discovered in UK Norway rats (Rattus norvegicus Berk.) in 1958 and 
has been present ever since. The possible detrimental impact of resistance on effective rodent control was 
quickly recognised and, for almost three decades, extensive research was conducted on the geographical 
distribution and severity of anticoagulant resistance in UK rats. Various schemes for the eradication of 
resistant rats were also implemented. At first, surveys showed resistance only to the first-generation 
anticoagulants, such as warfarin, chlorophacinone and coumatetralyl, but later resistance to the more 
potent second-generation anticoagulants, such as difenacoum and bromadiolone, was also discovered. 
Unlike some European countries, where only one or two resistance mutations occur, virtually all known 
rat resistance mutations occur in the UK and five are known to have significant impacts on anticoagulant 
efficacy. Little is currently known of the geographical extent of anticoagulant resistance among Norway 
rats in the UK because no comprehensive survey has been conducted recently. At an operational level, 
anticoagulants generally retain their utility for Norway rat control but it is virtually impossible to control 
resistant rats in some areas because of restrictions on the use of the more potent resistance-breaking 
compounds. This paper describes the development of resistance in Norway rats in the UK, outlines the 
present situation for resistance management and introduces a new resistance management guideline from 
the UK Rodenticide Resistance Action Group (RRAG, 2010). 
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Background 
Effective rodent control in the UK relies upon the anticoagulant rodenticides but resistance to them is 
widespread. Early surveys of resistance in Norway rats (Rattus norvegicus Berk.) revealed foci scattered 
across much of England, as well as parts of Scotland and Wales. One such survey, conducted in the years 
to 1972, showed resistance in 14 separate locations (Greaves and Rennison, 1974). The largest of these 
was an area on the Anglo-Welsh border, which became one of the most well-known and extensive UK 
resistance foci. Another substantial focus was first discovered in 1968 in Kent and East Sussex. It 
remained at least until 1974, when field trials of difenacoum were conducted there, but then was lost to 
sight. Among the other locations only one, first discovered in Hampshire in 1969, came to be a practical 
problem over a significant area (Greaves and Cullen-Ayres, 1988). It was thought that many of the other 
resistance foci recorded in 1974 had either died out naturally or had been removed by efforts at 
eradication (Greaves, 1995) but subsequent events have shown that neither was likely the case. 
Resistance testing and resistance mutations in the UK 
Laymen who hear the term ‘resistant’ often think that it is synonymous with the word ‘impervious’. In 
other words rats said to be resistant to a particular anticoagulant cannot be killed by it. This is very rarely 
so and all resistance testing requires a degree of qualitative interpretation. This was certainly the case 
with the feeding test used to distinguish resistant from susceptible rats in the early work of Greaves and 
Rennison (1974) and is even more so with the blood-clotting response (BCR) test which came to replace 
it (Prescott et al., 2007). A degree of certainty was provided, however, when a new genetical test was 
developed for resistance by workers based in Germany (see Pelz et al., 2005). For the first time it became 
possible to examine the DNA of individual rats and know for certain if they possessed a genetical 
resistance mutation. However, detailed biological work is still required to determine the practical impacts 
on operational rat control of a resistance mutation identified by DNA sequencing. Nevertheless, this test 
has revolutionised the study of anticoagulant resistance in the UK, and world-wide. A list of DNA 
mutations found at UK rat resistance foci, and locations of some of their foci, is given in Table 1. 
Knowledge of resistance in UK continues to increase and a new focus, or more likely an old one that had 
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remained undetected for many years, was recently identified in Kent with a DNA mutation not 
previously found in the UK (Prescott et al., 2011). 
Tab. 1 Known anticoagulant resistance mutations in Norway rats in UK (from Pelz et al., 2005; Prescott et al., 
2011) 
Resistance mutation Abbreviated mutation name Where present 
Leucine128Glutamine L128Q Central Southern Scotland, Yorkshire, Lancashire 
Tyrosine139Serine Y139S Anglo-Welsh border 
Leucine120Glutamine L120Q Hampshire, Berkshire 
Tyrosine139Cysteine Y139C Gloucestershire, Norfolk, Lincolnshire, Yorkshire,  
  SW Scotland 
Tyrosine139Phenylalanine Y139F Kent 
Phenylalanin63Cysteine F63C Cambridge/Essex 
Argenine33Proline N33P Nottinghamshire 
 
UK Rodenticide Resistance Action Group (RRAG) Guidelines 
Laboratory and field studies conducted previously in the UK, and elsewhere, provide an understanding of 
the effects of some of these mutations on operational rat control. The practical impacts of two (F63C, 
N33P) are unknown. Among the remainder, two mutations (L128Q, Y139S) confer resistance to the first-
generation anticoagulants but are largely susceptible to compounds of the second-generation, such as 
difenacoum and bromadiolone. These compounds are recommended for use against them and, more 
generally, anticoagulants are effective for rat control in the UK. However, three widely-distributed 
mutations (L120Q, Y139C, Y139F) confer a degree of resistance to bromadiolone and difenacoum. 
Resistance management is compromised at sites with these mutations because UK regulations, unlike 
those proposed under the Biocidal Products Directive, restrict potentially effective anticoagulants, 
brodifacoum, difethialone and flocoumafen, to use ‘indoors’, making them virtually useless for rat 
control. The reason for this restriction is concern about secondary poisoning of wildlife (Carter and Burn, 
2000). Consequently, rat control practitioners continue to use bromadiolone and difenacoum at sites 
where they are resisted. This situation, in existence for about 25 years in the UK, has probably 
exacerbated the severity of anticoagulant resistance and promoted its spread (Greaves, 1995). RRAG 
Guidelines (RRAG, 2010) state the obvious, namely that anticoagulant compounds should not be used 
where there is resistance to them. Where bromadiolone and difenacoum resistance occurs, and rats 
cannot be controlled by other means, a procedure is proposed whereby those wishing to control resistant 
rats apply to the UK Health and Safety Executive to use brodifacoum, difethialone or flocoumafen ‘in 
and around buildings’. It remains to be seen whether this proposal is acceptable to UK authorities and 
whether the applications can be administered in a timely and cost-effective manner. 
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